1. Scrip
  2. >>Business
  3. >>Financing

VC Investment Surges In Q2 As Financial Market Recovery Momentum Builds

Anecdotal Evidence Of Improvement Backed By Data

 
• By Mandy Jackson

Even after removing Xaira’s unusual $1bn seed financing, Evaluate’s data show that biopharma venture capital fundraising increased from the first to the second quarter and from Q2 of last year.

venture capital funding. green papaka, text on page wooden background.
VC funding rose across categories in the second quarter • Source: Shutterstock

Venture capital investment in the biopharmaceutical industry is on an undeniable upswing, with two quarters in a row of fundraising in 2024 that outpace the activity seen in 2023, according to data from Evaluate Pharma. In Q2, 143 companies raised $8.08bn, up from Q1 when 132 raised $6.53bn.

The first quarter of 2024 also represented a big boost, with the highest dollar amount of biopharma venture capital raised since Q2 of 2022. (Also see "Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate" - Scrip, 12 April, 2024.) The two-quarter trend seems to confirm commentary this year – first at the J.P. Morgan Healthcare Conference in January and then at the BIO International Convention in June – that while fundraising remains constrained relative to the boom years of 2020 and 2021, financial market conditions are improving

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.